By VETTAPHARMA reporter – Derek Roche: Pfizer reported that a Braftovi (encorafenib)-based regimen nearly doubled median progression-free survival in patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer, according to new findings from Cohort 3 of the Phase III BREAKWATER study presented at the 2026 American Society of Clinical Oncology Annual Meeting.
Patients treated with Braftovi in combination with cetuximab and FOLFIRI achieved a median progression-free survival of 15.2 months compared with 8.3 months for patients receiving FOLFIRI with or without bevacizumab. The regimen demonstrated a statistically significant 56% reduction in the risk of disease progression or death versus the comparator arm (HR 0.44; 95% CI, 0.27–0.70; p=0.0002).
Updated overall survival data also favored the targeted regimen. Pfizer reported a 44% reduction in the risk of death (HR 0.56; 95% CI, 0.34–0.94), with median overall survival not yet reached compared with 20.3 months in the control arm after approximately 20 months of follow-up. At 18 months, 72% of patients receiving the Braftovi regimen were expected to be alive versus 54.5% of patients receiving comparator therapy.
BREAKWATER Cohort 3 evaluated Braftovi plus cetuximab and FOLFIRI in patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer, one of the most aggressive molecular subtypes of the disease. BRAF mutations occur in approximately 8% to 12% of metastatic colorectal cancer cases and are associated with significantly worse outcomes compared with non-mutated disease.
The findings expand on previously reported BREAKWATER data supporting use of Braftovi-based targeted combinations in the first-line setting. Earlier Phase III results evaluating Braftovi with cetuximab and mFOLFOX6 demonstrated significant improvements in both progression-free survival and overall survival, leading to regulatory approvals in BRAF V600E-mutant metastatic colorectal cancer.
Safety findings remained consistent with the established profiles of Braftovi, cetuximab and FOLFIRI. Grade 3 or higher adverse events occurred in 70.4% of patients receiving the Braftovi combination compared with 80.9% in the comparator arm, while no new safety signals were identified.
Metastatic colorectal cancer remains the third most common cancer globally and the second leading cause of cancer-related death. Patients with BRAF V600E-mutant disease historically have had limited targeted treatment options and poor prognosis, making molecularly directed therapies a major area of clinical focus.
For patients, the data suggest that targeted inhibition of the BRAF pathway combined with anti-EGFR therapy and chemotherapy may substantially delay disease progression while extending survival. From a commercial perspective, the results further strengthen Pfizer’s precision oncology portfolio and reinforce Braftovi’s position as a cornerstone targeted therapy in BRAF-mutated colorectal cancer.
Quick FAQs
1. What is Braftovi?
Braftovi (encorafenib) is an oral BRAF kinase inhibitor used to treat cancers driven by BRAF mutations.
2. What were the key BREAKWATER Cohort 3 results?
The regimen reduced the risk of disease progression or death by 56% and improved median progression-free survival to 15.2 months versus 8.3 months.
3. What is the BREAKWATER study?
BREAKWATER is a Phase III trial evaluating Braftovi-based targeted combinations in previously untreated BRAF V600E-mutant metastatic colorectal cancer.
4. What is BRAF V600E-mutant metastatic colorectal cancer?
It is an aggressive subtype of colorectal cancer driven by a BRAF mutation and associated with poorer clinical outcomes.
5. What overall survival benefit was reported?
The regimen reduced the risk of death by 44%, with median overall survival not yet reached versus 20.3 months for comparator therapy.
6. Why are these findings important?
The results reinforce targeted first-line treatment approaches for a patient population historically associated with poor prognosis and limited therapeutic options.
